Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares


You May Also Like

Humanigen CEO to Present at Inaugural LD Micro Virtual Conference

BRISBANE, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company ...

Servier licenses GLPG1972 in osteoarthritis from Galapagos

Mechelen, Belgium; Suresnes Cedex, France; 27 July 2017, 22.00 CET, regulated information - As ...